US 12,492,170 B2
Tetrahydro-1H-benzazepine compound as potassium channel modulator, preparation method and use thereof
Bo Liang, Shanghai (CN); Qiu Jin, Shanghai (CN); Huanming Chen, Shanghai (CN); Zhijun Zhang, Shanghai (CN); and Bo Hua, Shanghai (CN)
Assigned to SHANGHAI ZHIMENG BIOPHARMA, INC., Shanghai (CN)
Appl. No. 17/614,780
Filed by Shanghai Zhimeng Biopharma Inc., Shanghai (CN)
PCT Filed May 26, 2020, PCT No. PCT/CN2020/092401
§ 371(c)(1), (2) Date Nov. 29, 2021,
PCT Pub. No. WO2020/238917, PCT Pub. Date Dec. 3, 2020.
Claims priority of application No. 201910473074.X (CN), filed on May 31, 2019.
Prior Publication US 2022/0227713 A1, Jul. 21, 2022
Int. Cl. C07D 223/16 (2006.01); C07D 409/06 (2006.01)
CPC C07D 223/16 (2013.01) [C07D 409/06 (2013.01)] 9 Claims
 
1. A compound represented by formula A or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein,
R1 is a substituted or unsubstituted group selected from the group consisting of C6-10 aryl and 4-7 membered heteroaryl containing 1-3 heteroatoms selected from N, O or S, and the substituted means being substituted by one or more halogen substituents
R2 and R3 are each independently C1-6alkyl;
R4 is selected from the group consisting of C1-6 alkyl and C3-6 cycloalkyl; and
m is selected from the group consisting of 0, 1, 2, and 3.